Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given an average recommendation of “Moderate Buy” by the eighteen analysts that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $54.94.

NTLA has been the topic of a number of research analyst reports. The Goldman Sachs Group lowered their price target on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Barclays lowered their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. William Blair reaffirmed a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research note on Monday, November 18th. Oppenheimer decreased their price target on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Monday, November 11th. Finally, Chardan Capital raised their price objective on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research report on Monday, November 18th.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $12.13 on Friday. Intellia Therapeutics has a one year low of $11.34 and a one year high of $34.87. The company’s fifty day moving average price is $14.08 and its 200-day moving average price is $19.43. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -2.23 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s revenue was down 24.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.38) earnings per share. Equities research analysts expect that Intellia Therapeutics will post -5.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 5.7% in the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock worth $251,849,000 after purchasing an additional 659,651 shares during the period. State Street Corp grew its holdings in shares of Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after purchasing an additional 780,754 shares during the last quarter. Geode Capital Management LLC increased its stake in Intellia Therapeutics by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after buying an additional 49,367 shares during the period. FMR LLC lifted its holdings in Intellia Therapeutics by 5.0% during the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company’s stock valued at $48,077,000 after buying an additional 111,104 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after buying an additional 371,189 shares during the period. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.